- Visibility0
- Citations0
- Sentiment50
- Site quality87
- AI readiness14
AI assistants do not name Incyte in any of the 60 answers about the healthcare market, while the typical company in this sector is named in 3.3% of answers. Incyte's overall score is 26 out of 100, ranking 1,729th of 2,047 companies. Its website passes 2 out of 14 technical checks for AI tool readiness.
We asked 15 unbranded questions about the healthcare market: none named Incyte. AI assistants named it in none of 60 answers. The typical healthcare company is named in 3.3% of answers. By how often it is named, Incyte ranks 69 of 105 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
The company is not named in this answer
“Are there assistance programs for high-cost medications in hematology or oncology?”
Yes — there are patient assistance programs (PAPs) and copay-support programs for many high-cost hematology and oncology medications. ASH notes that drug manufacturers and some private foundations operate PAPs that can reduce high copays and coinsurance for brand-name hematology drugs.
Examples from the provided results include:
Manufacturer assistance programs for specific drugs such as aprepitant through the Merck Access Program, nilotinib through Novartis’ Patient Assistance Foundation, and dasatinib through BMS Access Support and the BMS Patient Assistanc …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 0: Not yet agent-ready. Agents struggle to find basic information about the site.
- 2 of robots.txt, Sitemap, Link headers
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapNot met
Serve an XML sitemap and reference it from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 16 of 100 · 97% of checks could run · checked on October 5, 2026 · incyte.com · 2,047 companies scanned
2 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- Not metXML sitemapstudy: 73.2%
- Not metHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotpartly
- ClaudeBotpartly
- Anthropic-AIpartly
- Google-Extendedpartly
- Applebot-Extendedpartly
- Meta-ExternalAgentpartly
- FacebookBotpartly
- Bytespiderpartly
- CCBotpartly
- Diffbotpartly
- Omgilibotpartly
- OAI-SearchBotpartly
- Claude-SearchBotpartly
- PerplexityBotpartly
- Applebotpartly
- Amazonbotpartly
- YouBotpartly
- ChatGPT-Userpartly
- Claude-Userpartly
- Perplexity-Userpartly
- DuckAssistBotpartly
- MistralAI-Userpartly
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as S&P 500.
- How do small molecule and biologic medicines in inflammation treatment compare?
- Oncology clinical trial designs: traditional vs. adaptive approaches
- What are the most promising novel therapies in hematology right now?
- What to do if a patient is not responding to a novel hematology treatment?
- How are innovative oncology medicines being integrated in community oncology practice?
- What alternatives exist for patients who are ineligible for bone marrow transplant in blood disorders?
- Are newer targeted cancer therapies a better option than traditional chemotherapy for aggressive cancers?
- Best emerging treatments for autoimmune conditions with limited existing options?
- Are there assistance programs for high-cost medications in hematology or oncology?
- How are biopharmaceutical companies addressing unmet needs in oncology care?
- How to manage side effects from recently approved immunomodulatory medicines?
- Is it worth pursuing new biopharmaceutical therapies for rare autoimmune disorders?
- Why are prices for breakthrough cancer therapies so high in the United States?
- Pipeline medicines vs. established standard-of-care therapies in hematology—what’s different?
- When are oral targeted therapies preferred over infusions in autoimmune disease management?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.